Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study
Este estudio analizó la respuesta inmunitaria y la seguridad de la vacuna BNT162b2 (Pfizer-BioNTech) frente a la COVID-19 en 134 residentes mayores de 65 años de cinco centros de atención de larga estancia en Albacete (España), con distintos grados de fragilidad y discapacidad. Los participantes rec...
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Ētahi atu kaituhi: | |
| Hōputu: | Journal Article |
| Reo: | Ingarihi |
| Ngā marau: | |
| Urunga tuihono: | Path |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ngā tūemi rite: Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study
- High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in Long-Term Care Facilities
- HEPATITIS B CARRIERS IN A CENTRE FOR THE MENTALLY RETARDED IN FINLAND AND IMMUNOGENICITY OF HEPATITIS B VACCINE
- COVID-19 vaccines - what older Canadians need to know
- EXPERIENCE WITH HEPATITIS B VACCINATION IN NURSES IN A HOSPITAL FOR THE MENTALLY HANDICAPPED
- COVID-19 risk factors amongst 14.786 care home residents: an observational longitudinal analysis including daily community positive test rates of COVID-19, hospital stays and vaccination status in Wales (UK) between 1 September 2020 and 1 May 2021
- HEPATITIS B VACCINATION PRACTICES IN STATE AND FEDERAL PRISONS